Wednesday, January 24, 2018 10:15 PM ET
Insider Selling at Atara Biotherapeutics (ATRA) Continues with Significant Sale
One insider — Isaac E Ciechanover, Director and Officer — today, sold 48,500 shares of Atara Biotherapeutics having a market value of approximately $1,677,279, as disclosed in a form 4 document filed with the SEC. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 101,100 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 149,600 shares and have averaged 49,867 shares per transaction over this time period.
The number of insider buy/sell trades at Atara Biotherapeutics is greater than that of the 280 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 336 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by Atara Biotherapeutics insiders is lower than its peers. Within the peer group there were 48,687,603 shares purchased and 42,207,712 shares sold with company insiders acquiring 29,454 shares on average over this time period.
Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in composing and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.